safety profile News
Most Popular safety profile Story
Insulin retreats blamed for Generex stock drop
Generex is firmly in the camp that sees the glass as half full. After seeing its share price slide 16 percent yesterday, the developer attributed the sudden setback to decisions by Eli Lilly, Read more...
Latest Headlines
- June 4, 2008
- March 11, 2008
- February 28, 2008
- January 8, 2008
- December 4, 2007
- November 20, 2007
- October 1, 2007
- January 23, 2007
- December 20, 2006
- December 18, 2006
- November 28, 2006
- October 22, 2006
- October 12, 2006
- September 12, 2006
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
